Drugs of abuse tests require highly selective, robust assays. Aptamers are helping to deliver new assays for more sensitive and simpler tests. According to the UN Office on Drugs…

Anti-hapten antibodies are difficult and slow to generate limiting cheap and efficient bioanalysis in this field. Our proprietary methods offer standard assay formats, such as ELISA and lateral flow…

There is a growing need for easy to use, point of care tests. A technology where aptamers can be used to achieve this is in lateral flow assays. A…

28/09/2020 Collaboration to produce a rapid test for the COVID-19 coronavirus infection Aptamer Group, is pleased to announce that it has entered into a collaboration with Cytiva,…

Arron Tolley, CEO of Aptamer Group discusses the teams progress on COVID-19 tests: 17/06/2020 Scientists at York-based biotechnology company Aptamer Group are using their expertise to develop a COVID-19…